• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

GeneThera to Collaborate With Leading Mexican University on Live Animal Testing

Posted on: Thursday, 30 March 2006, 12:00 CST

In line with its strategic direction to commercialize a live animal test for several veterinary diseases, including Mad Cow Disease, GeneThera (OTCBB: GTHA) announces that it will commence live animal testing with a leading Mexican university.

This collaboration was initiated from a scientific department of the university that has been doing ongoing research into Johne's disease (paratuberculosis).

Commenting on this new venture with the university, Dr. Tony Milici, CEO of GeneThera, said, "The recent press release we put out stating we have commenced operations within Mexico has brought forth a tremendous amount of interest from parties within Mexico. We are thrilled that this university has sought to establish a collaborative facility to further both GeneThera's and the research of the Mexican academic community working on TSE testing."

Mr. Sergio Gonzalez, partner in GeneThera's new joint venture in Mexico, said, "I am very pleased to have been able to bring GeneThera and its outstanding scientific work to the attention of this university. I believe a collaboration of this sort between Dr. Milici and our brightest research minds will quickly lead to further results in the field of Johne's testing.

Johne's (pronounced "Yo-nees") disease is a contagious bacterial disease of the intestinal tract. The disease is also called paratuberculosis. Johne's disease occurs in a wide variety of animals, but most often in ruminants. Ruminants are hoofed mammals that chew their cud and have a 3-4 chambered stomach. Some of the more common ruminants are: cattle, sheep, goats, deer, antelope, and bison. Johne's disease has been reported in all of these animals but is most commonly seen in dairy cattle.

ABOUT GENETHERA, INC.:

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colo. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the healthcare industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johne's Disease.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.

Source: Business Wire

More News in this Category